MaxCyte initiated with an Overweight at Stephens

Stephens initiated coverage of MaxCyte (MXCT) with an Overweight rating and $6 price target The company is in the early stages of making prudent investments in offerings that expand its reach of the market, the analyst tells investors in a research note. The firm added that while this strategy is still in the early innings, it believe the strategy has the potential to drive long-term revenue growth.